middl
east
respiratori
syndrom
mer
coronaviru
merscov
origin
identifi
saudi
arabia
caus
mer
outbreak
high
mortal
middl
east
europ
rais
seriou
concern
pandem
potenti
therefor
develop
effect
vaccin
crucial
prevent
spread
futur
pandem
previou
studi
shown
subcutan
sc
vaccin
recombin
protein
contain
receptorbind
domain
rbd
merscov
fuse
fc
human
igg
rbdfc
induc
strong
system
neutral
antibodi
respons
vaccin
mice
compar
local
system
immun
respons
induc
rbdfc
via
intranas
sc
immun
pathway
found
vaccin
merscov
rbdfc
induc
system
humor
immun
respons
compar
induc
sc
vaccin
includ
neutral
antibodi
robust
system
cellular
immun
respons
significantli
higher
local
mucos
immun
respons
mous
lung
studi
suggest
potenti
develop
merscov
rbd
protein
effect
safe
mucos
candid
vaccin
prevent
respiratori
tract
infect
caus
merscov
recent
emerg
middl
east
respiratori
syndrom
mer
coronaviru
merscov
caus
sever
acut
respiratori
syndrom
sar
like
diseas
high
casefat
rate
cfr
decemb
total
laboratoryconfirm
case
infect
merscov
includ
death
report
http
wwwwhointcsrdon
continu
threat
merscov
call
develop
effect
vaccin
unlik
sarscov
caus
agent
sar
use
human
angiotensinconvert
enzym
function
receptor
merscov
util
novel
coronaviru
receptor
human
dipeptidyl
peptidas
also
known
viral
entri
target
cell
differ
sarscov
merscov
broader
tissu
tropism
capabl
infect
varieti
human
nonhuman
cell
type
includ
primat
porcin
bat
cell
maintain
broad
replic
capabl
mammalian
cell
line
nevertheless
consid
similar
merscov
sarscov
belong
genu
betacoronaviru
approach
develop
effect
sar
vaccin
expect
applic
mer
vaccin
develop
previou
studi
sar
reveal
system
humor
cellular
immun
respons
play
import
role
prevent
viral
infect
base
product
high
neutral
antibodi
cell
immun
respons
addit
mucos
immun
respons
repres
secretori
iga
also
crucial
clearanc
infect
viru
studi
sar
suggest
system
humor
cellular
local
mucos
immun
respons
also
import
prevent
mer
infect
induc
highli
potent
neutral
antibodi
protect
viru
infect
receptorbind
domain
rbd
sarscov
spike
protein
shown
attract
target
develop
vaccin
sar
similar
rbd
sarscov
protein
recent
studi
shown
rbd
merscov
protein
also
mediat
viru
bind
receptor
thu
plausibl
rbd
merscov
could
compar
effect
vaccin
target
fc
human
igg
immun
enhanc
use
import
fusion
tag
capabl
coexpress
viral
protein
promot
protein
express
purif
improv
immunogen
fusion
protein
previou
studi
shown
recombin
sarscov
rbd
protein
fuse
human
fc
induc
highli
potent
immun
respons
complet
protect
vaccin
mice
sarscov
challeng
also
demonstr
recombin
fc
fusion
protein
contain
conserv
sequenc
hemagglutinin
influenza
viru
elicit
stronger
neutral
antibodi
respons
without
fusion
fc
crossprotect
mice
diverg
strain
viru
challeng
confirm
abil
fc
enhanc
immunogen
fusion
protein
potenti
mechan
may
associ
abil
promot
correct
fold
fusion
protein
allow
protein
bind
fc
receptor
fcr
contain
antigenpres
cell
apc
notabl
immunogen
human
fc
region
mice
detriment
effect
immunogen
specif
antigen
fusion
protein
evidenc
fact
merscov
rbd
protein
fuse
human
igg
fc
could
elicit
high
titer
influenza
viru
merscov
antibodi
respons
respect
vaccin
mice
thu
construct
express
recombin
protein
contain
rbd
residu
merscov
protein
fuse
fc
human
igg
srbdfc
hereinaft
name
rbdfc
demonstr
previou
studi
protein
induc
signific
antibodi
respons
neutral
activ
subcutan
sc
vaccin
pathway
evalu
abil
protein
elicit
immun
respons
via
intranas
rout
compar
present
studi
system
mucos
immun
respons
induc
sc
vaccin
pathway
emphas
import
develop
inbas
mucos
vaccin
prevent
mer
infect
cell
express
merscov
rbdfc
protein
purchas
american
type
cultur
collect
atcc
manassa
va
femal
balbc
mice
age
week
use
studi
anim
hous
anim
facil
new
york
blood
center
anim
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
anim
protocol
approv
committe
ethic
anim
experi
new
york
blood
center
permit
number
construct
express
purif
recombin
merscov
rbdfc
protein
done
previous
describ
briefli
gene
encod
rbd
protein
residu
merscov
amplifi
pcr
use
synthes
codonoptim
merscov
sequenc
genbank
access
templat
fuse
fc
human
igg
use
express
vector
hereinaft
name
fc
invivogen
san
diego
ca
merscov
residu
plu
histidin
amplifi
insert
express
vector
jiangsu
taizhou
haiyuan
protein
biotech
co
ltd
china
protein
express
cell
cultur
supernat
purifi
protein
affin
chromatographi
ge
healthcar
piscataway
nj
merscov
rbdfc
ninta
superflow
qiagen
valencia
ca
merscov
accord
manufactur
instruct
done
use
previous
describ
immun
protocol
modif
briefli
mice
primevaccin
either
sc
rbdfc
gmous
plu
adjuv
montanid
seppic
fairfield
nj
lmous
rbdfc
gmous
plu
adjuv
poli
c
invivogen
lmous
mice
anesthet
isofluran
vaccin
mice
initi
boost
twice
day
first
vaccin
boost
end
month
addit
two
group
mice
vaccin
dose
pb
plu
adjuv
sc
poli
c
use
neg
control
mous
sera
collect
monthli
basi
month
lung
wash
splenocyt
collect
day
postlast
vaccin
fig
collect
sampl
detect
humor
system
igg
antibodi
respons
subtyp
local
mucos
iga
antibodi
respons
neutral
antibodi
well
cellular
immun
respons
merscov
srbdspecif
igg
subtyp
iga
antibodi
respons
test
elisa
collect
mous
sera
lung
wash
use
previous
describ
protocol
briefli
serial
dilut
mous
sera
lung
flush
ad
microtit
plate
precoat
merscov
rbdfc
merscov
protein
respect
plate
incub
c
h
follow
four
wash
pb
contain
tween
pbst
bound
antibodi
react
horseradish
peroxidas
hrp
conjug
antimous
igg
ge
healthcar
iga
invitrogen
carlsbad
ca
c
h
four
wash
substrat
tetramethylbenzidin
tmb
invitrogen
ad
plate
reaction
stop
ad
n
h
absorb
nm
measur
elisa
plate
reader
tecan
san
jose
ca
cell
respons
immun
mice
detect
intracellular
cytokin
stain
follow
flow
cytometri
analysi
previous
describ
briefli
splenocyt
stimul
without
merscov
protein
sarscov
rbd
protein
neg
control
day
c
mous
immun
sampl
collect
immun
respons
detect
four
group
mice
micegroup
respect
sc
primevaccin
merscov
rbdfc
protein
plu
adjuv
vaccin
group
pb
plu
adjuv
respect
control
mice
initi
boost
twice
day
boost
end
month
immunogen
vaccin
rout
sera
collect
monthli
basi
ten
day
postlast
vaccin
mous
sera
lung
wash
collect
detect
igg
subtyp
iga
antibodi
elisa
neutral
antibodi
neutral
assay
mous
splenocyt
collect
day
postlast
vaccin
detect
cellular
immun
respons
flow
cytometr
analysi
co
presenc
golgiplug
tm
contain
brefeldin
lml
bd
bioscienc
san
jose
ca
phorbol
myrist
acet
pma
ngml
ionomycin
gml
sigmaaldrich
st
loui
mo
use
posit
control
cell
fix
use
cytofixcytoperm
tm
plu
kit
accord
manufactur
protocol
bd
bioscienc
stain
directli
conjug
apc
fitc
pe
bd
bioscienc
min
c
appropri
isotypematch
control
cytokin
includ
stain
stain
cell
analyz
use
flow
cytometri
facscalibur
bd
bioscienc
data
evalu
facsdiva
softwar
bd
bioscienc
titer
neutral
antibodi
immun
mous
sera
lung
wash
detect
previous
describ
modif
briefli
serum
sampl
dilut
serial
tissu
cultur
plate
incub
room
temperatur
h
infecti
merscoverasmu
medic
center
emc
well
transfer
result
mixtur
duplic
well
confluent
vero
cell
h
incub
viru
control
well
exhibit
advanc
virusinduc
cytopath
effect
cpe
neutral
capac
individu
serum
lung
wash
specimen
assess
determin
presenc
absenc
cpe
neutral
antibodi
titer
express
reciproc
highest
dilut
serum
lung
wash
complet
inhibit
virusinduc
cpe
least
well
data
present
mean
standard
deviat
sd
statist
signific
differ
vaccin
group
calcul
student
test
use
spss
statist
softwar
valu
p
consid
signific
evalu
abil
merscov
rbdfc
induc
system
humor
immun
respons
via
rout
well
compar
differ
immun
respons
induc
via
sc
rout
collect
mous
sera
differ
time
point
use
elisa
detect
igg
antibodi
specif
merscov
srbd
protein
shown
fig
singl
prime
dose
vaccin
rbdfc
elicit
signific
igg
antibodi
respons
merscov
igg
antibodi
rapidli
increas
higher
level
postlast
vaccin
comparison
singl
prime
dose
sc
vaccin
rbdfc
induc
rel
higher
level
specif
igg
antibodi
respons
although
sc
boost
vaccin
protein
elicit
increas
level
igg
antibodi
last
vaccin
antibodi
titer
similar
induc
via
vaccin
sera
sc
vaccin
merscov
rbdfc
could
bind
specif
merscov
protein
without
fusion
fc
fig
endpoint
igg
antibodi
titer
reach
similar
level
sc
respect
fig
postlast
vaccin
expect
merscov
rbdfc
scand
invaccin
mous
sera
abl
bind
significantli
merscov
rbdfc
protein
fig
signific
differ
igg
product
seen
sc
vaccin
group
p
fig
assess
capabl
rbdfc
protein
induc
longterm
antibodi
respons
compar
result
sc
vaccin
expect
elev
igg
specif
merscov
detect
invaccin
mous
sera
quickli
reach
higher
level
month
although
igg
antibodi
titer
induc
rout
decreas
lower
level
month
could
rapidli
increas
level
equal
attain
sc
rout
month
boost
end
month
sc
rout
vaccin
end
month
help
increas
igg
antibodi
highest
titer
suggest
inject
rbdfc
much
like
inject
rbdfc
sc
pathway
abl
stimul
longterm
humor
immun
respons
vaccin
mice
multipl
boost
vaccin
requir
maintain
strong
antibodi
respons
fig
collect
mous
lung
wash
sc
vaccin
merscov
rbdfc
protein
elicit
similar
level
merscov
igg
antibodi
fig
immun
sc
pb
control
group
induc
background
level
igg
antibodi
respons
fig
evalu
serum
igg
subtyp
antibodi
respons
reveal
vaccin
merscov
rbdfc
elicit
merscov
antibodi
respons
similar
induc
sc
vaccin
p
fig
note
valu
mer
igg
detect
use
sera
mice
preimmun
day
last
vaccin
data
present
mean
standard
deviat
sd
five
mice
per
group
b
abil
igg
bind
merscov
protein
detect
use
sera
day
postlast
vaccin
data
present
mean
sd
five
mice
per
group
variou
dilut
point
merscov
c
srbd
specif
igg
endpoint
titer
detect
use
sera
day
postlast
vaccin
data
present
geometr
mean
titer
gmt
sd
five
mice
per
group
e
detect
longterm
antibodi
respons
use
sera
collect
month
day
postlast
vaccin
data
present
mean
igg
endpoint
titer
sd
five
mice
per
group
f
reactiv
lung
wash
igg
antibodi
specif
merscov
detect
use
mous
lung
wash
day
postlast
vaccin
data
present
mean
sd
five
mice
per
group
antibodi
merscov
protein
rel
higher
antibodi
sc
vaccin
suggest
merscov
rbdfc
induc
slightli
bias
antibodi
respons
background
level
serum
antibodi
test
antigen
detect
sc
pb
control
group
fig
result
suggest
mice
vaccin
merscov
rbdfc
protein
induc
strong
system
humor
igg
antibodi
respons
sera
lung
reflect
result
similar
sc
vaccin
mice
assess
abil
merscov
rbdfc
protein
induc
local
mucos
immun
respons
mucos
iga
antibodi
respons
detect
elisa
collect
mous
lung
wash
iga
vaccin
mous
sera
includ
control
shown
fig
vaccin
rbdfc
elicit
strong
merscov
iga
antibodi
respons
lung
wash
significantli
higher
induc
rbdfc
sc
immun
p
fig
detect
igg
subtyp
elisa
vaccin
mous
sera
merscov
b
c
antibodi
induc
sc
vaccin
detect
use
sera
day
postlast
vaccin
endpoint
titer
sampl
determin
highest
dilut
yield
nm
valu
greater
twice
similarli
dilut
serum
sampl
collect
preimmun
optic
densiti
data
present
gmt
sd
five
mice
per
group
data
suggest
vaccin
merscov
rbdfc
protein
sc
rout
induc
strong
local
mucos
immun
respons
repres
high
level
mucos
iga
particular
lung
wash
mice
invaccin
test
protein
contain
merscov
iga
antibodi
still
highli
detect
even
dilut
test
sampl
howev
background
level
iga
detect
mous
lung
wash
sampl
sc
pb
control
group
fig
addit
notic
rbdfcvaccin
mous
sera
contain
iga
antibodi
sampl
maintain
slightli
higher
titer
rout
compar
sc
rout
p
evid
suggest
vaccin
merscov
rbdfc
abl
induc
stronger
local
mucos
immun
respons
achiev
sc
rout
fig
detect
iga
antibodi
respons
elisa
vaccin
mous
lung
wash
sera
merscov
iga
antibodi
induc
sc
vaccin
detect
use
mous
lung
wash
serial
dilut
sera
b
day
postlast
vaccin
data
lung
wash
present
mean
sd
five
mice
per
group
endpoint
titer
serum
sampl
determin
highest
dilut
yield
nm
valu
greater
twice
similarli
dilut
serum
sampl
collect
preimmun
optic
densiti
data
serum
sampl
present
gmt
sd
five
mice
per
group
evalu
compar
cellular
immun
respons
potenti
induc
sc
vaccin
merscov
rbdfc
cell
respons
detect
splenocyt
immun
mice
cell
surfac
marker
intracellular
cytokin
stain
follow
flow
cytometr
analysi
shown
fig
sc
vaccin
merscov
rbdfc
protein
capabl
induc
substanti
cell
immun
respons
repres
high
frequenc
cell
stimul
splenocyt
merscov
protein
particular
vaccin
rbdfc
elicit
significantli
higher
frequenc
merscov
cell
slightli
higher
level
cell
cell
popul
compar
sc
vaccin
protein
importantli
sarscov
rbd
protein
control
fail
stimul
splenocyt
deriv
merscov
rbdfcvaccin
mice
irrespect
rout
immun
also
mice
immun
via
either
sc
rout
merscov
cell
respons
detect
frequenc
splenocyt
splenocyt
b
cell
surfac
marker
follow
intracellular
cytokin
stain
use
flow
cytometr
analysi
splenocyt
merscov
rbdfcvaccin
mice
incub
recombin
merscov
protein
panel
b
b
sarscov
rbd
protein
control
panel
e
f
b
splenocyt
mice
pb
control
also
stimul
merscov
panel
c
b
sarscov
rbd
protein
panel
g
h
b
frequenc
cell
express
percentag
cell
data
upper
left
bottom
right
corner
graph
repres
frequenc
cell
sampl
test
triplic
present
mean
sd
five
mice
per
group
number
bold
indic
signific
differ
correspond
sc
vaccin
group
experi
repeat
three
time
similar
result
obtain
pb
control
group
reveal
merscov
cell
respons
taken
togeth
result
suggest
vaccin
via
rout
merscov
rbdfc
protein
abil
elicit
stronger
cellular
respons
sc
rout
repres
cell
investig
abil
merscov
rbdfc
induc
neutral
antibodi
via
rout
sera
contain
highest
igg
antibodi
eg
day
vaccin
lung
wash
detect
neutral
merscov
infect
vero
cell
data
fig
demonstr
sc
vaccin
rbdfc
could
induc
equal
strong
neutral
antibodi
respons
merscov
immun
mous
sera
p
notabl
vaccin
rbdfc
induc
significantli
higher
level
neutral
antibodi
collect
mous
lung
wash
sc
vaccin
rbdfc
indic
immun
rbdfc
abl
induc
stronger
mucos
immun
respons
neutral
activ
fig
sc
pb
control
group
induc
background
level
neutral
antibodi
titer
vaccin
mous
sera
lung
wash
result
suggest
rbdfc
potenti
develop
mucos
vaccin
vaccin
prevent
merscov
infect
mer
novel
emerg
infecti
respiratori
tract
diseas
first
identifi
saudi
arabia
spread
countri
middl
east
europ
increas
number
infect
death
diseas
develop
effect
safe
vaccin
includ
one
capabl
induc
mucos
immun
respons
site
viru
infect
crucial
prevent
spread
merscov
potenti
pandem
use
revers
genet
system
fulllength
infecti
cdna
clone
merscov
genom
success
construct
bacteri
artifici
chromosom
provid
possibl
develop
attenu
virus
mer
mucos
vaccin
candid
previou
studi
sar
reveal
vaccin
target
rbd
sarscov
protein
effect
induc
potent
system
immun
respons
neutral
activ
complet
protect
vaccin
anim
viru
challeng
addit
intranas
vaccin
sarscov
rbdbase
vaccin
abl
elicit
strong
mucos
immun
respons
provid
longterm
protect
sarscov
infect
studi
indic
protein
particularli
rbd
sarscov
import
target
sar
vaccin
develop
mucos
immun
respons
addit
system
immun
also
play
signific
role
prevent
sarscov
infect
experi
base
sar
studi
suggest
protein
includ
rbd
merscov
anoth
coronaviru
genu
betacoronaviru
could
promis
target
develop
vaccin
mer
expect
recent
studi
shown
recombin
modifi
vaccinia
viru
ankara
mva
express
fulllength
protein
merscov
mvamerss
produc
high
level
serum
antibodi
vaccin
mice
neutral
merscov
infect
previou
studi
also
show
sc
vaccin
recombin
vaccin
target
rbd
residu
merscov
fuse
fc
human
igg
rbdfc
protein
elicit
humor
igg
antibodi
respons
favor
neutral
activ
truncat
fcfuse
rbd
protein
merscov
induc
strong
neutral
antibodi
respons
vaccin
mice
suggest
rbd
merscov
inde
promis
vaccin
target
studi
compar
capabl
rbdfc
protein
induc
system
humor
cellular
immun
respons
local
mucos
immun
respons
via
sc
vaccin
adjuv
use
poli
c
vaccin
montanid
isa
sc
immun
poli
c
synthet
doublestrand
rna
polym
previous
report
effici
mucos
adjuv
influenza
vaccin
montanid
isa
miner
oilbas
adjuv
shown
previou
studi
effect
induc
strong
influenza
ha
merscov
srbdspecif
humor
immun
respons
neutral
activ
via
sc
rout
interestingli
result
studi
demonstr
system
humor
igg
antibodi
respons
subtyp
induc
vaccin
pathway
compar
induc
sc
pathway
collect
mous
sera
lung
wash
specif
rbd
merscov
specif
vaccin
pathway
induc
rel
higher
level
note
similar
level
consid
import
antibodydepend
cellular
cytotox
viru
neutral
detect
vaccin
mous
sera
via
sc
rout
data
suggest
merscov
rbdfc
immun
rout
capabl
elicit
similar
greater
system
humor
antibodi
respons
elicit
sc
pathway
vaccin
mice
significantli
similarli
high
titer
serum
neutral
antibodi
rais
mice
vaccin
dose
rbdfc
protein
via
sc
rout
p
fig
higher
attain
dose
sc
vaccin
protein
increas
vaccin
dose
lead
improv
neutral
antibodi
titer
indic
need
multipl
vaccin
rbd
protein
contain
residu
merscov
induc
stronger
neutral
antibodi
respons
maintain
month
merscov
infect
human
respiratori
tract
present
sever
acut
respiratori
syndrom
like
sar
accordingli
vaccin
capabl
induc
strong
local
mucos
immun
repres
secretori
iga
would
help
prevent
merscov
infect
data
indic
merscov
iga
antibodi
respons
neutral
activ
vaccin
mous
lung
elicit
vaccin
merscov
rbdfc
protein
significantli
higher
induc
sc
vaccin
protein
confirm
abil
rbdfc
induc
strong
local
mucos
immun
via
rout
previou
studi
sarscov
rbdbase
vaccin
demonstr
induct
mucos
iga
via
pathway
play
import
role
prevent
sarscov
infect
previous
demonstr
presenc
high
titer
mucos
iga
mice
serum
neutral
antibodi
low
still
fulli
protect
sarscov
challeng
replic
thu
reason
prospect
high
titer
local
mucos
neutral
iga
serum
neutral
antibodi
induc
vaccin
merscov
rbdfc
protein
shown
studi
effect
inhibit
merscov
infect
protect
anim
merscov
challeng
previou
report
sar
studi
reveal
sarscov
proteinspecif
andor
cell
immun
respons
could
induc
vaccin
anim
memori
cell
well
memori
cell
still
detect
recov
patient
year
sar
infect
suggest
cellular
immun
respons
also
play
role
prevent
viral
infect
similarli
compar
sc
rout
adjuv
montanid
isa
found
merscov
rbdfc
abl
induc
higher
frequenc
merscov
cell
respons
vaccin
mous
spleen
rout
presenc
poli
c
adjuv
higher
cellular
immun
respons
induc
rbdfc
vaccin
rout
compar
sc
rout
possibl
differ
adjuv
use
correspond
pathway
report
scvaccin
cancer
vaccin
formul
montanid
isa
picibanil
adjuv
abl
induc
antigenspecif
cell
respons
major
vaccin
patient
administr
yersinia
pesti
lcrv
protein
fuse
antidec
antibodi
adjuv
poli
c
induc
high
frequenc
secret
cell
well
polyfunct
cell
airway
lung
vaccin
mice
thu
optim
merscov
candid
vaccin
presenc
differ
adjuv
essenti
evalu
role
cellular
immun
respons
addit
humor
mucos
immun
protect
merscov
infect
anim
challeng
model
mer
becom
avail
summar
compar
system
humor
cellular
immun
respons
local
mucos
immun
respons
via
sc
vaccin
recombin
rbd
protein
contain
residu
merscov
fuse
fc
human
igg
rbdfc
found
vaccin
merscov
rbdfc
induc
system
humor
immun
respons
includ
neutral
antibodi
compar
induc
sc
vaccin
robust
system
cellular
immun
respons
significantli
higher
local
lung
mucos
immun
respons
vaccin
mice
therefor
result
suggest
possibl
develop
protein
effect
safe
mucos
mer
vaccin
prevent
merscov
infect
stop
spread
merscov
